{"id":6166,"date":"2022-03-17T07:30:00","date_gmt":"2022-03-17T07:30:00","guid":{"rendered":"https:\/\/realheart.se\/mfn_news\/realheart-recruits-clinical-strategist-and-electronics-expert\/"},"modified":"2022-03-17T07:30:00","modified_gmt":"2022-03-17T07:30:00","slug":"realheart-recruits-clinical-strategist-and-electronics-expert","status":"publish","type":"mfn_news","link":"https:\/\/realheart.se\/sv\/mfn_news\/realheart-recruits-clinical-strategist-and-electronics-expert\/","title":{"rendered":"Realheart recruits clinical strategist and electronics expert"},"content":{"rendered":"
Press release 17\u00a0March\u00a02022<\/p>\n

Realheart has brought on board Australian consultant Sara Diab, who will support the company's regulatory and clinical strategy, and electronics expert Nicolas Barabino, based in Spain, who will support the development of the clinical control unit for the Realheart TAH.<\/strong><\/div>\n

Sara Diab is a former IVA nurse who now works as a medical device specialist with over 10 years of experience in the development of artificial hearts \u2013 everything from ethics applications and trial planning to data collection and reporting.<\/span><\/span><\/span><\/span><\/p>\n

''Sara Diab has an incredibly important skill set based on many years of developing artificial hearts, but her experience in healthcare is just as important in planning for future clinical trials where our heart will be used by patients," said Ina Laura Perkins, CEO of Realheart.<\/span><\/span><\/span><\/span><\/p>\n

Nicolas Barabino is an expert in medical device innovations such as active implants and various forms of life support devices. He has a PhD in microelectronics and holds two patents related to blood pumps. He has been involved for the last 10 years in the development of heart pumps and brain implants in Uruguay, France, and Spain, working with global medical devices companies. He currently lives and works in Spain as a consultant. <\/span><\/span><\/span><\/span><\/p>\n

Nicolas Barabino will be based in Spain, but he will also work from Sweden and Australia where Realheart's partner Hydrix, who is developing the clinical control unit, is located. Sara Diab will work mostly from Australia but will also participate in research studies internationally. Hereby the company is strengthening its international network in Europe and Australia.<\/span><\/span><\/span><\/span><\/p>\n

Both have already joined the company. Realheart plans to start clinical trials in 2023. <\/span><\/span><\/span><\/span><\/p>\n

\n

For more information please contact:<\/span><\/span><\/strong><\/span><\/p>\n

Ina Laura Perkins, CEO<\/span><\/span><\/p>\n

Phone: +46(0)70 406 49 21\u00a0<\/span><\/span><\/p>\n

E-mail: inalaura.perkins@realheart.se<\/span><\/span><\/p>\n

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, Phone: +46 11 32 30\u00a0732, email:\u00a0ca@skmg.se<\/a><\/span><\/span><\/p>\n<\/div>\n

\n

Scandinavian Real Heart AB develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Realheart TAH has a unique, patented design that resembles that of the natural human heart. The artificial heart consists of a four-chamber system (two atriums and two chambers) which provides the opportunity to generate a physiologically adapted blood flow that mimics the body's natural circulation. A unique concept in the medical technology world.<\/span><\/em><\/span><\/span><\/span><\/p>\n<\/div>\n